López ME

Language: Spanish
References: 18
Page: 76-80
PDF size: 89.21 Kb.

ABSTRACT

Pulmonary hypertension is a condition frequently seen and associated to many cardiovascular diseases and can become a hemodynamic complication in postoperative period. This can require the integral management in the intensive care room. In the last years we have many new concepts about the pathophysiology of this condition and new therapeutic options. In this paper we review the current strategies for the management of this condition.

REFERENCES

1. LÓPEZ MORA E: Tratamiento de la hipertensión arterial pulmonar perioperatoria. Arch Cardiol Mex 2002; 72 Supl 1: S122-25.

2. LÓPEZ MORA E: Manejo de la hipertensión arterial pulmonar grave postbomba. Arch Cardiol Mex 2004; 74 Supl 2: S509-14.

3. LEVIN ER: Endotelins: N Engl J Med 1995; 6: 356-63.

4. CARTEAUX JP, ROUXS, SIAGHY M, SCHJOTH B, DELOTON P: Acute pulmonary hypertension after cardiopulmonary bypass in pig: the role of endoyenom endothelin. Eur J Cardiothorac 1999; 15: 346-351.

5. CACOUB P, DORENT R, MAISTRE G, NATAF P, CARAYON A: Endothelin- 1 in primary pulmonary hypertension and the Einsenmenger syndrome. Am J Cardiol 1993; 5: 448-50.

6. ISHIKAWA S, MIYACHI T, SAKAI S, USHNOHAMA H, SAGAWA K: Elevated levels of plasma edothlis-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. J Thorac Cardiovasc Surg 1995; 1: 271-3.

7. DINCER E, PRESBERG K: Current management of pulmonary hypertension. Clin Pulm Med 2004;

8. 11: 40-53.

9. GHOFRANI H, PEPKE-ZABA J, BARBERA J, CHANIK R, KEOGH A: Nitric oxide pathway and phosphodienterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 688-72S.

10. MURATA T, SAT K, HORI M: Decreased endothelial nitric oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hipoxia induced pulmonary hypertension. J Biol Chem 2002; 277: 44085-44092.

11. COOKE J: A novel mechanism for pulmonary arterial hypertension. Circulation 2003; 108: 1420-21. 11. BLAISE G, LANGLEBEN D, HUBERT B: Pulmonary arterial hypertension. Anesthesiology 2003; 99: 1415-32.

12. STOBIERSKA B, AWAD H, MICHLER R: The evolving management of acute right side heart failure in cardiac transplant recipients. J Am Coll Cardiol 2001; 38: 923-31.

13. PAMBOUKIAN S, CARERE R, WEBB J, COOK R, DYANCKOVA B, ABEL J: The use of milrinone in pretransplant assessment of patients with congestive heart failure an pulmonary hypertension. J Heart Lung Transpl 1199; 18: 367-71.

14. LEPORE J, DEC W, ZAPOL W, BLOCH K, SEMIGRAN M: Combined administration of intravenous dipyridamole and inhaled nitric oxide to assess reversibility of pulmonary arterial hypertension in potential cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 1950-6.

15. HARALDSSON A, KIELER-JENSEN NRICKSTEN S: THE additive pulmonary vasodilatory effects of inhaled prostaciclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001; 93: 1439-45.

16. LAMARCHE Y, MALO O, THORIN E, DENAULT A, CARRIER M, ROY J, PERRAULT LP: Inhaled but no intravenous milrinone prevents endothelial dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005; 130: 83-92.

17. MICHELAKIS E, TYMCHAK W, LIEN D, WEBTER L, HASHIMOTO K: Oral sildenafil is an effective and specific vasodilator in patients with pulmonary arterial hipertension. Comparison with inhaled nitric oxide. Circulation 2002; 105: 2398-2403.

18. KRAMM T, EBERLE B, GUTH S, MAYER E: Inhaled iloprost to control residual pulmonary hipertension following pulmonary endarterectomy. Eur J Cardiothorac Surg 2005; 28: 882-88.